Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aschantin
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Aschantin (frequently misspelled as aschatin in some literature) is a natural tetrahydrofurofuran-type lignan isolated from *Magnoliae Flos* (the dried flower buds of *Magnolia* species). It exhibits anti-inflammatory, anti-allergic, and anticancer properties. Aschantin acts as a mammalian target of rapamycin (mTOR) kinase inhibitor, directly targeting the active pocket of the mTOR kinase domain. In the context of breast cancer-mediated bone destruction, aschantin suppresses the expression and secretion of parathyroid hormone-related protein (PTHrP) in metastatic breast cancer cells and reduces the bone-resorbing activity of osteoclasts by inhibiting matrix metalloproteinase-9 (MMP-9) and cathepsin K.
- Other names
- (+)-aschantinaschatin
02
Targets
CYP2C8 (Cytochrome P450 2C8)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on aschantin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aschantin.